Jupiter Wellness (NASDAQ: JUPW), a leading developer of cannabidiol (“CBD”)-based medical therapeutics and wellness products, has initiated a clinical study evaluating the treatment of herpes labialis (cold sores) for its prescription topical cream candidate JW-100. The company believes this trial may be the first to analyze the efficacy of a combination CBD-aspartame product in the treatment of herpes labialis. JUPW’s topical cream, JW-100, features a dual mechanism of action and relief combined with CBD’s potential ability to induce apoptosis in epithelial cells infected with Kaposi sarcoma-associated herpes virus, with aspartame’s analgesic and anti-inflammatory properties. The study will include 40 patients enrolled through clinical sites in both Europe and Asia. Patients will have been diagnosed with recurrent herpes labialis infection (“HSV”) with initial infection at least a year previously. “We are rapidly advancing our clinical pipeline with our third indication,” said Jupiter CEO Brian John. “Herpes cold sores are common, with an estimated 48% of Americans aged 14-49 having had the HSV-1 virus. We believe JW-100 has the potential to treat and provide relief with fewer side effects than the treatments on the market today. This exploratory clinical trial is in line with a Phase I FDA study, and therefore we believe the resulting data will be a valuable addition to the Investigational New Drug (‘IND’) application we plan to file with the FDA for advanced stage trials in the U.S.”
To view the full press release, visit https://cnw.fm/AmQ3p
About Jupiter Wellness Inc.
Jupiter Wellness is a leading developer of cannabidiol (“CBD”)-based medical therapeutics and wellness products. The company’s clinical pipeline of prescription CBD-enhanced, skin-care therapeutics address indications including eczema, burns, herpes cold sores and skin cancer. Jupiter generates revenues from a growing line of proprietary over-the-counter skin-care products including its flagship CaniSun(TM) sunscreen and other wellness brands sold through its robust distribution platform. For additional information about this company, please visit www.JupiterWellnessInc.com.
NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://cnw.fm/JUPW
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.